Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

Media Contact for 908 Devices
Barbara Russo
brusso@908devices.com

Investor Contact for 908 Devices
Carrie Mendivil
IR@908devices.com

Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling.

In the field of bioprocessing, the continuous monitoring of glucose and lactate levels is crucial for optimizing cell culture conditions and thereby the research and development of biopharmaceutical products. Accurate measurement of these parameters allows for better control of the bioreactor environment, leading to improved productivity and reduced time to market.

908 Devices’ MAVEN provides highly precise, on-line monitoring and control of glucose and lactate without any loss of bioreactor volume, enabling biopharma scientists to maintain optimal nutrient and metabolite concentrations, even at very low levels. Data from MAVEN is collected and supervised through Getinge’s advanced controllers. It can set up control loops, recipe functionality and advanced control, and has the capacity to measure from up to two bioreactors simultaneously.

“We are thrilled to collaborate with 908 Devices on this joint solution to make our customers’ life in the lab easier. This means continuous visibility into concentration changes, continuous control of glucose levels, and the ability to adjust control strategies based on real-time measurements, such as starting feeding or stopping cultivation. This enables our customers to increase productivity and go faster to market,” explains Timo Keijzer, Director Product Marketing at Getinge.

Timo’s emphasis on seamless lab workflows is echoed by Christopher D. Brown, Chief Product Officer and Co-founder at 908 Devices, who adds: “We’re excited to partner with Getinge as we share a mutual passion to enable our biopharma customers with modern bioprocess automation tools for control of critical process parameters, thereby increasing their process understanding and accelerating development workflows. In addition, implementing robust control strategies in development optimizes product performance and facilitates a scalable process.”

The MAVEN device will be compatible with Getinge’s Livit Flex controller and connected through Livit Links sensor ports. Find out more about Getinge’s bioreactors.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements for 908 Devices

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219224577/en/

We’re excited to partner with Getinge as we share a mutual passion to enable our biopharma customers with modern bioprocess automation tools for control of critical process parameters, increasing their process understanding and accelerating workflows.